Patent · US Active

Materials and methods for treatment of alpha-1 antitrypsin deficiency

US11851653B2 · kind B2 · utility

0Cited by

132References

5Claims

0Family size

Assignee

CRISPR THERAPEUTICS AG · CH

Inventors

Chad A. Cowan · Cambridge, US
Roman Lvovitch Bogorad · Cambridge, US
Jeffrey Li · Santa Clara, US
Ante Sven Lundberg · Cambridge, US
Matthias John · Hallstadt, DE
Jeffrey Stebbins · Nutley, US
Thao Thi NGUYEN · Cambridge, US

Key dates

Filing date	Dec 1, 2016
Grant date	Dec 26, 2023
Priority date	—
Expiry date	Jul 19, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/80
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application provides materials and methods for treating a patient with Alpha-1 antitrypsin deficiency (AATD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing the SERPINA1 gene in a cell by genome editing.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.